DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,565 filers reported holding DANAHER CORPORATION in Q2 2020. The put-call ratio across all filers is 1.06 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $179,733 | +27.7% | 724,264 | +23.5% | 0.41% | +31.0% |
| Q2 2023 | $140,784 | -4.4% | 586,521 | -0.2% | 0.32% | -14.8% |
| Q1 2023 | $147,240 | -22.3% | 587,493 | -17.3% | 0.37% | -25.9% |
| Q4 2022 | $189,386 | -99.9% | 710,695 | +3.6% | 0.50% | -5.6% |
| Q3 2022 | $179,602,000 | +10.9% | 686,257 | +6.0% | 0.53% | +12.7% |
| Q2 2022 | $161,969,000 | -12.0% | 647,170 | +4.6% | 0.47% | +4.9% |
| Q1 2022 | $184,128,000 | -9.3% | 618,606 | -0.4% | 0.45% | -9.1% |
| Q4 2021 | $203,100,000 | +12.6% | 621,013 | +6.3% | 0.49% | -2.0% |
| Q3 2021 | $180,344,000 | +27.4% | 584,144 | +11.8% | 0.50% | +22.0% |
| Q2 2021 | $141,516,000 | +27.8% | 522,424 | +5.4% | 0.41% | +12.2% |
| Q1 2021 | $110,692,000 | +9.9% | 495,631 | +9.9% | 0.37% | -2.6% |
| Q4 2020 | $100,695,000 | +9.5% | 450,999 | +3.7% | 0.38% | -7.4% |
| Q3 2020 | $92,000,000 | +81.7% | 435,031 | +50.0% | 0.41% | +27.5% |
| Q2 2020 | $50,632,000 | +31.1% | 290,081 | +6.3% | 0.32% | +8.1% |
| Q1 2020 | $38,617,000 | -7.7% | 272,846 | -0.4% | 0.30% | +15.6% |
| Q4 2019 | $41,856,000 | -18.5% | 273,834 | -24.0% | 0.26% | -19.7% |
| Q3 2019 | $51,345,000 | -25.3% | 360,352 | -25.3% | 0.32% | -7.5% |
| Q2 2019 | $68,743,000 | +18.9% | 482,180 | -13.6% | 0.34% | +0.3% |
| Q1 2019 | $57,835,000 | +9.1% | 558,386 | +7.4% | 0.34% | -2.0% |
| Q4 2018 | $53,002,000 | -8.4% | 519,938 | -6.9% | 0.35% | +2.6% |
| Q3 2018 | $57,835,000 | +27.5% | 558,386 | +22.0% | 0.34% | +15.9% |
| Q2 2018 | $45,354,000 | +53.2% | 457,739 | +50.8% | 0.30% | +45.3% |
| Q1 2018 | $29,606,000 | -0.8% | 303,598 | -16.5% | 0.20% | -12.1% |
| Q4 2017 | $29,834,000 | 0.0% | 363,409 | 0.0% | 0.23% | -0.4% |
| Q3 2017 | $29,834,000 | +2.3% | 363,409 | +5.4% | 0.23% | 0.0% |
| Q2 2017 | $29,163,000 | -2.9% | 344,811 | -1.2% | 0.23% | -15.6% |
| Q1 2017 | $30,030,000 | +18.1% | 349,005 | +7.3% | 0.28% | +1.9% |
| Q4 2016 | $25,425,000 | +5.0% | 325,395 | +3.7% | 0.27% | +0.7% |
| Q3 2016 | $24,221,000 | +29.8% | 313,835 | +68.5% | 0.27% | +26.4% |
| Q2 2016 | $18,656,000 | -5.5% | 186,278 | -10.4% | 0.21% | -9.4% |
| Q1 2016 | $19,738,000 | +5.8% | 207,831 | +5.0% | 0.23% | +9.3% |
| Q4 2015 | $18,654,000 | +17.2% | 197,987 | +4.6% | 0.21% | +10.3% |
| Q3 2015 | $15,918,000 | -13.7% | 189,246 | -12.5% | 0.19% | -11.4% |
| Q2 2015 | $18,438,000 | -11.0% | 216,236 | -10.8% | 0.22% | -15.1% |
| Q1 2015 | $20,710,000 | -8.3% | 242,536 | -6.7% | 0.26% | -9.5% |
| Q4 2014 | $22,583,000 | +21.7% | 259,994 | +6.1% | 0.28% | +13.5% |
| Q3 2014 | $18,558,000 | +2.8% | 245,059 | +7.7% | 0.25% | -7.4% |
| Q2 2014 | $18,045,000 | +10.0% | 227,518 | +3.4% | 0.27% | +3.8% |
| Q1 2014 | $16,411,000 | -4.1% | 220,077 | -1.0% | 0.26% | -7.1% |
| Q4 2013 | $17,115,000 | +7.3% | 222,299 | -3.2% | 0.28% | +0.4% |
| Q3 2013 | $15,949,000 | +66.8% | 229,709 | +52.4% | 0.28% | +49.7% |
| Q2 2013 | $9,559,000 | – | 150,710 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |